Kazuo Hasegawa

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

M. Fukuoka, H Niitani, Atsushi Suzuki et al. · Journal of Clinical Oncology · 1992 · 435 citations

Medicine, Oncology, Pharmacology +16

Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

Takao Yoshioka, Takashi Fujita, Tsutomu Kanai et al. · Journal of Medicinal Chemistry · 1989 · 220 citations

Pharmacy, Medicinal Chemistry, Pharmacology +7

Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

Teiichiro Koga, Yohko Shimada, Masao Kuroda et al. · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · 1990 · 168 citations

Life Sciences, Biochemistry, Pharmacology +14

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu et al. · International Journal of Clinical Oncology · 2019 · 153 citations · Full text

Medicine, Oncology, Metastasis +12

Reversible hyperintensity lesion on diffusion-weighted MRI in hypoglycemic coma

Takeshi Aoki, Tomoe Sato, Kazuo Hasegawa et al. · Neurology · 2004 · 105 citations

Medicine, Neurology, Radiology +14